GOODWILL(SH:688246) Mei Ri Jing Ji Xin Wen·2025-11-29 00:38Core Viewpoint - The company Jiahe Meikang has faced significant financial corrections and disciplinary actions from the Shanghai Stock Exchange due to accounting errors that have led to substantial reductions in reported profits for 2022 and 2023 [2][3][4]. Financial Corrections - In April, Jiahe Meikang announced corrections to its financial reports, reducing the net profit for 2022 by 3.4463 million yuan, which is 8.46% of the original amount, and for 2023 by 10.213 million yuan, which is 50.35% of the original amount [2][3]. - The total profit adjustments for 2022 amounted to 4.0544 million yuan (14.81% reduction) and for 2023, 11.3478 million yuan (169.95% increase in losses) [3]. Disciplinary Actions - The Shanghai Stock Exchange issued a disciplinary notice, criticizing the company's former chairman and financial officer, and requiring the company to submit a rectification report within one month [4]. - The company has been instructed to improve its compliance and information disclosure practices [4]. Financial Performance - Jiahe Meikang reported a significant increase in losses, with a net profit of -256 million yuan for 2024, reflecting a year-on-year decline of 893.31% [5]. - The company’s revenue for the first half of the year was 219 million yuan, a decrease of 27.22% year-on-year, with net losses expanding to -116 million yuan, compared to -27.47 million yuan in the same period last year, marking a 323.29% increase in losses [6]. Market Position - Despite being recognized as the leading company in the electronic medical record market in China for eleven consecutive years, Jiahe Meikang's recent financial struggles contrast sharply with its market position [5]. - The company serves over 650 tertiary hospitals, accounting for more than one-third of such hospitals in the country, indicating its significant market presence [5].